Overview

Cyclophosphamide and Alemtuzumab In Lymphoma

Status:
Terminated
Trial end date:
2018-01-30
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: - Cyclophosphamide - Alemtuzumab
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Genzyme, a Sanofi Company
Sanofi
Treatments:
Alemtuzumab
Cyclophosphamide